ACS Medicinal Chemistry Letters

Viewpoint

Inhibitors of LRRK2 as Treatment for Parkinson's Disease

caused by its abnormal activity such as PD and cancer.


Patent Highlight

Ahmed F. Abdel-Magid*

Therachem Research Medilab (India) Pvt. Ltd., Jaipur, India

Title:	Pyrazolopyridines as Inhibitors of the Kinase LRRK2				
Patent Application Number:	WO 2012/038743 Al	Publication Date:	March 29, 2012		
Priority Application:	US 61/385,522	Priority Date:	September 22, 2010		
	GB 1015949.9				
Inventors:	Chan, B.; Chen, H.; Estrada, A.; Shore, D.; Sweeney, Z.; McIver, E.				
Assignee Company:	Medical Research Council Technology, London WC1H 9LT, GB				
	Genentech Inc., San Francisco, California 94080-4990, United States				
Disease Area:	Cancer and neurodegenerative diseases such as Parkinson's disease	Biological Target:	Kinases: preferably LRRK kinase; more preferably, LRRK2		
Summary:	The pyrazolopyridines represented by formula (I) are capable of inhibiting one or more kinases, more particularly, LRRK2, and may provide a treatment of a variety of disorders caused by this kinase, including cancer and neurodegenerative diseases such as Parkinson's disease (PD). The leucine-rich repeat kinase 2 (LRRK2) is a member of the leucine-rich repeat kinase family (LRRK). Mutations of this enzyme are associated with hereditary and nonhereditary forms of PD. In the patent application mentioned, there are almost 40 known single amino acid substitution mutations on LRRK2 linked to autosomal-dominant PD. Inhibition of the LRRK2 kinase with any of the molecules represented by formula (I) may potentially offer a treatment for any of the disorders				


Important Compound Classes:





Key Structures:

The following structures are representative examples of 239 total reported compounds using their listed numbers in the patent application; their K_i values are reported below:



		52	59	196
Biological Assay:	In Vitro LRRK2 Assay			
	This assay was used to determin inhibition values.	e a compound's potency in inh	ibiting activity of LRRK2 by	determining $K_{i app'}$ IC ₅₀ , or percent
Biological Data:	The patent application reported the affinity values for LRRK2 (K_{ν} in μ M) for 119 of the 239 listed compounds.			
	The K_i values ranged from 0.000	03 and 0.0024 μM (for compo	unds 52 and 59, respectively)) to 0.858 μ M (for compound 196).
Claims:	1: This claim, the only composit	tion of matter claim, lists 239 s	pecific structural variations of	f formula (I).

701

2–10: Claim pharmaceutical composition and therapeutic use of compounds for treating cancer and neurodegenerative diseases resulting from abnormal LRRK2 activity.

Published: July 27, 2012



t Review Articles:	Dorval, V.; Hebert, S. S. Front. Neurodegener. 2012, 3, 12.
	Kramer, T.; Lo Monte, F.; Göring, S.; Okala Amombo, G. M.; Schmidt, B. ACS Chem. Neurosci. 2012, 3 (3), 151-160.
	Liu, G.; Aliaga, L.; Cai, H. Future Neurol. 2012, 7 (2), 145–153.
	Kumar, A.; Cookson, M. R. Expert Rev. Mol. Med. 2011, 13.
	Dihanich, S.; Manzoni, C. J. Neurosci. 2011, 31 (27), 9787–9788.

AUTHOR INFORMATION

Corresponding Author

*Address: 1383 Jasper Drive, Ambler, Pennsylvania, 19002, United States. Tel: 215-913-7202. E-mail: afmagid@comcast.net.

Notes

Recent

The authors declare no competing financial interest.